PRINCETON, N.J., May 21, 2020 -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced changes to its executive leadership team. Michael McBreen, who is.
Integra LifeSciences Holdings Corporation (IART), a leading global medical technology company, announced today certain unaudited preliminary first quarter financial results. The company also announced that it will release full first quarter 2020 financial results on Thursday, May 7, 2020, prior to market open. Given the existing uncertainty related to COVID-19, the company is withdrawing its guidance for the first quarter and full-year 2020 previously issued on February 19, 2020.
Integra LifeSciences Holdings Corporation (IART), a leading global medical technology company, announced today that its 2020 Annual Meeting of Stockholders (the “Meeting”) location will change from its headquarters to a virtual meeting by remote communication. As noted in our Proxy Statement, the Company determined to change the location from a physical meeting to a virtual meeting due to the continuing health concerns regarding the COVID-19 pandemic, restrictions on gathering issued by the State of New Jersey and the U.S. Centers for Disease Control and Prevention, and to continue to support the health and well-being of our employees, stockholders, and directors. No stockholders will be permitted to attend the 2020 Annual Meeting in person.
Integra (IART) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Completion of integration activities, scale expansion, product launches, and venturing into faster-growing markets drive Interga's (IART) sales within Codman Surgical.
Integra LifeSciences Holding Corporation (IART), a leading global medical technology company, today announced positive clinical and economic data on Integra® Bilayer Wound Matrix (IBWM) in complex lower extremity reconstruction. This data from two retrospective studies was recently published by Stephen J. Kovach, M.D., FACS, and John P. Fischer, M.D., MPH, FACS, from the University of Pennsylvania Health System, in Plastic and Reconstructive Surgery, the official journal of the American Society of Plastic Surgeons.
Here are five GARP stocks to brace your portfolio from recessionary hurdles.
PRINCETON, N.J., May 11, 2020 -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it will participate.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Zacks.com featured highlights include: TGNA, IART, PCG, CLGX and ABC
IART earnings call for the period ending March 31, 2020.
This regulatory clearance is expected to bolster Merit Medical Systems' (MMSI) cardiovascular segment.
Integra's (IART) first-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.
PRINCETON, N.J., May 07, 2020 -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the.
The primary aim of this initiative by Syneos Health (SYNH) is to address the predicted ventilator deficiency in the wake of the coronavirus pandemic.
IART vs. ABMD: Which Stock Is the Better Value Option?
Q1 2020 Integra Lifesciences Holdings Corp Earnings Call
Integra (IART) delivered earnings and revenue surprises of -20.00% and 0.46%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Integra (IART) unable to measure the magnitude of total loss it has to bear out of the coronavirus-led economic damages, and hence, withdraws the full-year guidance.